Compare iShares MSCI South Korea ETF (EWY) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Gilead Sciences, Inc. — how do they compare? iShares MSCI South Korea ETF trades at $177.22 (market cap $26.25B), while Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 6.9× iShares MSCI South Korea ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while iShares MSCI South Korea ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 47 Days and Gilead Sciences, Inc. for 111 Days on average.
| EWY | GILD | |
|---|---|---|
Market Cap | $26.25B | $182.40B |
Volume | 19,056,075 | 4,469,821 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $155.80 |
52-Week Low | $80.72 | $116.74 |
Typical Hold Time | 47 Days | 111 Days |
Enterprise Value | — | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, trades at $177.22, down 3.54% amid broad Asian market pressure from rising oil prices and US Treasury yields. Technical indicators show a bearish trend with support at $174 and resistance at $179, while RSI levels suggest potential oversold conditions. The ETF remains heavily concentrated in Samsung and SK hynix, benefiting from AI-driven memory demand but vulnerable to semiconductor cycle volatility.
Outlook remains cautious as geopolitical tensions and high concentration risk offset strong AI fundamentals. The ETF's 148% YoY gain highlights growth potential, but investors face headwinds from global monetary tightening and oil price shocks. Key catalysts include semiconductor investment developments and US-Korea trade relations.
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
